Memantine Clonmel

Memantine Hydrochloride, the active ingredient in Memantine Clonmel, is an NMDA receptor antagonist presented as an oral formulation for oral use. It is used to treat moderate to severe Alzheimer’s disease in adults and may help maintain daily functional abilities while supporting cognitive performance.

GNH USA supplies Memantine Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable quality assurance and regulatory compliance. Our distribution network ensures timely delivery across Europe, Asia, Africa and the Americas, adhering to local import requirements and cold‑chain standards where applicable.

Memantine is indicated for Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function. - Alzheimer's disease (moderate to severe): improves cognition and daily functional abilities. - Alzheimer's disease (behavioral symptoms): may reduce agitation and aggression in patients. - Alzheimer's disease (memory decline): may slow the rate of memory loss progression. - Alzheimer's disease (global function): supports overall neurological function and daily living activities. - Alzheimer's disease (caregiver support): may help maintain patient independence, easing caregiver burden.

Memantine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Seizures - Hallucinations or psychosis

When prescribing memantine, clinicians should consider the following precautions to ensure safe use. - Renal impairment: adjust dose or monitor renal function in patients with reduced kidney function. - Hepatic disease: use caution in patients with liver dysfunction and monitor liver enzymes. - Cardiovascular conditions: assess for potential blood pressure changes in patients with unstable cardiovascular disease. - Concomitant CNS disorders: monitor for increased confusion or sedation in patients with existing central nervous system disorders. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Memantine can interact with other medicines; interactions are classified by their clinical significance.

Major Interactions (Avoid): - Amantadine: combined use may increase risk of neuropsychiatric adverse effects. - NMDA agonists (e.g., D‑cycloserine): may reduce memantine’s therapeutic effect. - High-dose vitamin D supplements: may potentiate hypercalcemia risk.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: additive cognitive impairment may occur. - CNS depressants (e.g., benzodiazepines): may enhance sedation and dizziness. - Diuretics (e.g., furosemide): monitor electrolytes as memantine may affect renal clearance.